Hulusi Bulent Zeyneloglu

Hulusi Bulent Zeyneloglu

Auto-generated profile, based on publicly available information

Hulusi Bulent Zeyneloglu

Department of Obstetrics and Gynecology, Baskent University School of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1998 in Fertility and Sterility
Verified
Journal Article
Open access
HZHulusi B Zeyneloglu
Hulusi B Zeyneloglu
AAAydin Arici
Aydin Arici
DODavid L Olive
David L Olive
To determine the effect of hydrosalpinx on the establishment of pregnancy after IVF-ET. Metaanalysis. University medical center. All published reports (n=13) and abstracts (n=10) in English that examined the relation between hydrosalpinx and IVF-ET were included in the analysis. The metaanalysis was performed by first calculating the odds ratios for each trial and then combining them to obtain a pooled estimate of the odds ratio and a 95% confidence interval. Clinical pregnancy. A total of 5,569 cycles was reviewed in the group without hydrosalpinx, and a total of 1,144 was reviewed in the group with hydrosalpinx. The clinical pregnancy rate was approximately 50% lower in patients who had hydrosalpinx. Similarly, the implantation rate was decreased by 50%. These effects were observed also in thawed ET cycles. The abortion rate was more than twofold higher in patients who had hydrosalpinx. This metaanalysis suggests that hydrosalpinx is associated with a reduced chance of implantation and an increased risk of pregnancy loss.

1 February 2002 in Human Reproduction
Verified
Journal Article
Open access
PDF file
HYHakan Yaralı
Hakan Yaralı
BYBülent O. Yıldız
Bülent O. Yıldız
ADAygül Demirol
Aygül Demirol
HZHulusi B. Zeyneloğlu
Hulusi B. Zeyneloğlu
NYNuray Yiğit
Nuray Yiğit
ZKZehra Koray
Zehra Koray
BACKGROUND: This study aims to evaluate the impact of metformin on ovarian response when co-administered during recombinant (r)FSH using the low-dose step-up protocol in clomiphene citrate-resistant polycystic ovarian syndrome (PCOS) patients with normal glucose tolerance. METHODS AND RESULTS: Thirty-two patients were randomized to metformin (n = 16) and placebo (n = 16) groups. Hormonal assessment, a 75 g oral glucose tolerance test (OGTT) and a frequently sampled i.v. glucose tolerance test (FSIGTT) were performed before and after oral administration of metformin (850 mg twice daily) or placebo for 6 weeks. Recombinant FSH treatment was undertaken, thereafter, in women who did not ovulate on metformin (n = 10) or placebo (n = 15). There was no significant change in all insulin sensitivity indices in both groups. The only change noted was a decline in mean serum free testosterone concentration in the metformin group (P = 0.049). One patient on placebo and six patients on metformin ovulated spontaneously (P < 0.05). All parameters of ovarian response were comparable between the two groups during rFSH treatment. Combining the 6 week placebo or metformin-only period with a single rFSH treatment cycle, the overall ovulation rates were 75 and 94% in the placebo and metformin groups respectively (P > 0.05). The respective figures for pregnancy were 6.3 and 31.3% (P > 0.05). CONCLUSIONS: Metformin may restore ovulation with no improvement on insulin resistance in clomiphene citrate-resistant PCOS patients with normal glucose tolerance, but has no significant effect on ovarian response during rFSH treatment.

18 January 2007 in Human Reproduction
Verified
Journal Article
Open access
PDF file
MOMesut Oktem
Mesut Oktem
IEIbrahim Esinler
Ibrahim Esinler
DEDerya Eroglu
Derya Eroglu
NHNihan Haberal
Nihan Haberal
NBNilufer Bayraktar
Nilufer Bayraktar
HZHulusi B. Zeyneloglu
Hulusi B. Zeyneloglu
This prospective randomized-controlled animal study was designed to determine the effects of atorvastatin on experimentally induced endometriosis in a rat model. Thirty-seven Wistar-Albino rats in which endometriotic implants were induced were randomly divided into four groups. Group I (Low-dose atorvastatin group, eight rats) were given 0.5 mg kg−1 day−1 oral atorvastatin. Group II (High-dose atorvastatin group, 10 rats) were given 2.5 mg kg−1 day−1 oral atorvastatin. Group III were given a single dose of 1 mg kg−1 s.c. leuprolide acetate (GnRH agonist group, nine rats). Group IV were given no medication and served as controls (10 rats). All rats received the treatment for 21 days and were then euthanized to assess the implants' size, vascular endothelial growth factor (VEGF) level in peritoneal fluid and histological score. At the end of the treatment, the mean areas of implants were smaller and VEGF levels in peritoneal fluid were lower in Groups II and III than those in Group I and the control group (all P < 0.05). The mean areas of implants decreased from 41.2 ± 13.9 to 22.7 ± 13.9 mm2 after medication in Group II and decreased from 41.2 ± 18.1 to 13.1 ± 13.8 mm2 in Group III (both P < 0.05), whereas in Group I, the mean area increased from 43.0 ± 12.7 to 50.5 ± 13.9 mm2 (P < 0.05). High-dose atorvastatin caused a significant regression of endometriotic implants.

11 June 2014 in Seminars in Reproductive Medicine
Verified
Journal Article
Closed access
GOGogsen Onalan
Gogsen Onalan
HZHulusi Bulent Zeyneloglu
Hulusi Bulent Zeyneloglu
In vitro fertilization (IVF) is expensive, time consuming, and the most successful treatment of fertility; however, in general the cumulative chance of having a live birth with the treatment is still around 40%. Many couples still remain unsuccessful after several IVF attempts, causing deep impact on quality of life, and each failed cycle causing a financial burden. Several adjuvant therapies have been used along with IVF to increase the pregnancy rates for women with repeated implantation failure. Testing of adjuvant therapies in properly conducted randomized controlled trials is rarely done so that potential benefits and risks are unlikely to be clearly presented to patients and clinicians. In this review, we assessed the effects of adjuvants, such as growth hormone, androgens, and glucocorticoids to enhance oocyte number and quality; sildenafil, low-dose aspirin, heparin, corticosteroids, granulocyte colony-stimulating factor, endometrial injury, intrauterine injection of human chorionic gonadotropin, and intrauterine administration of autologous peripheral blood mononuclear cells to improve poor endometrial response; antioxidants, complementary and alternative medicine modalities, such as Chinese herbal medicine and acupuncture; and assisted hatching and preimplantation genetic screening to correct embryonic factors.

7 May 2008 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Open access
PDF file
FSFeride Iffet Sahin
Feride Iffet Sahin
ZYZerrin Yilmaz
Zerrin Yilmaz
OYOzge Ozalp Yuregir
Ozge Ozalp Yuregir
TBTugce Bulakbasi
Tugce Bulakbasi
OOOzge Ozer
Ozge Ozer
HZHulusi Bulent Zeyneloglu
Hulusi Bulent Zeyneloglu
Cytogenetic heteromorphisms are described as heritable variations at specific chromosomal regions without a proven impact on phenotype. We compared the presence of chromosome heteromorphisms in the karyotypes of two patient groups. The first group of patients consisted of 276 individuals of 138 infertile couples. The second group, consisted of 1,130 amniocentesis samples. This group was considered to be a sample of the fertile population, as the fetus being karyotyped is the result of a spontaneous pregnancy. Fetal karyotyping was made due to the standard indications for prenatal diagnosis, such as abnormal maternal serum screening results. Eighteen infertile patients (6.52%) and twenty fetuses (1.77%) were found to have chromosome heteromorphisms. The difference between the two groups was statistically significant (p < 0.0001). These results are consistent with other similar studies that suggest the yet undefined relationship between chromosome heteromorphisms and infertility.

1 October 2007 in Fertility and Sterility
Verified
Journal Article
Closed access
EYEmrah Yavuz
Emrah Yavuz
MOMesut Oktem
Mesut Oktem
IEIbrahim Esinler
Ibrahim Esinler
HTHavva Serap Toru
Havva Serap Toru
HZHulusi B. Zeyneloglu
Hulusi B. Zeyneloglu